Relative Bioavailability of Single Doses of Dabigatran Etexilate in Healthy Volunteers

Phase 1 Completed 24 enrolled Boehringer Ingelheim

NaSingle-groupOpen-labelTreatment

Study to investigate whether and to what extent the suggested P-glycoprotein (P-gp) inducer rifampicin affects plasma exposure of dabigatran.

Evaluation	Drug	Modality	Dose	Route
Subject	Dabigatran etexilate	Unknown	150 mg	Oral
Subject	Rifampin	Small molecule	600 mg	Oral

No indication recorded.